Search Site

Search form

Archived Press Releases

All Releases
View Summary Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation
Dec 19, 2013
PDF 23.3 KB
View Summary Vertex Sells INCIVO ® Product Royalty Rights for $152 Million
Nov 20, 2013
PDF 12.0 KB
View Summary Vertex To Present at Upcoming Investor Conferences
Nov 11, 2013
PDF 7.0 KB
View Summary Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK
Oct 29, 2013
PDF 12.1 KB
View Summary Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014
Oct 29, 2013
PDF 62.0 KB
View Summary Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study
Oct 18, 2013
PDF 22.1 KB
View Summary Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis
Oct 17, 2013
PDF 25.9 KB
View Summary Vertex Changes Timing of Third Quarter 2013 Earnings Call On October 29
Oct 10, 2013
PDF 7.5 KB
View Summary Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO™ (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations
Sep 30, 2013
PDF 17.1 KB
View Summary Vertex to Announce Third Quarter 2013 Financial Results on October 29
Sep 25, 2013
PDF 7.3 KB
View Summary Vertex To Present at Morgan Stanley Healthcare Conference
Sep 5, 2013
PDF 6.4 KB
View Summary Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference
Sep 3, 2013
PDF 15.5 KB
View Summary Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations
Jul 29, 2013
PDF 15.1 KB
View Summary Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs
Jul 29, 2013
PDF 63.8 KB
View Summary Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C
Jul 25, 2013
PDF 14.2 KB
View Summary Vertex Receives Australian Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)
Jul 9, 2013
PDF 16.8 KB
View Summary Vertex To Announce Second Quarter 2013 Financial Results On July 29
Jun 27, 2013
PDF 6.8 KB
View Summary Vertex Completes Redemption of Convertible Senior Subordinated Notes
Jun 18, 2013
PDF 6.2 KB
View Summary Vertex Announces Webcast of its Presentation at the Goldman Sachs 34th Annual Global Healthcare Conference
Jun 5, 2013
PDF 6.4 KB
View Summary Vertex Announces Presentation of Data at European Cystic Fibrosis Society Conference
Jun 5, 2013
PDF 16.8 KB
Showing 1-20 of 439 Page: 1 2 3 4 5 ... 22  Next 20